Archived News for Health Sector Professionals - August, 2022
Australian researchers have uncovered the oldest known evidence of a rare genetic condition.
Global study shows hot future
Researchers say by the end of this century, parts of Australia could see dangerous heat most days of the year.
Huge review finds Vitamin D helps
A large-scale study finds vitamin D supplementation seems to alleviate depressive symptoms in adults.
Moderna sues over vaccine IP
Moderna has sued Pfizer and BioNTech for patent infringement in the development of a COVID-19 vaccine.
Mouse model could spare studies
A new synthetic mouse embryo could reduce the use of experimental animals.
WA aims at 'period poverty'
Western Australia has become the last state to offer free period products in public secondary school.
Nature play needs assessed
Teachers say they want support for more ‘nature play’ in primary education.
Cancer links counted
Experts say that around half of all global cancer deaths are due to 34 risk factors.
Health app costs counted
People who used a mobile app or fitness tracker during the pandemic were almost two times more likely to meet physical activity guidelines, according to an international survey.
Housing response reviewed
Experts have reviewed the situations many Victorian public housing residents found themselves in during the COVID-19 pandemic.
Vaccine review released
The ANAO has reviewed Australia's COVID-19 vaccine rollout and found it came too late ...
AMP payouts lag
AMP has been slammed over “vanishingly small” compensation payouts for unlawful life insurance conduct.
Councils consider health levy
Several Tasmanian councils are looking at a medical levy to help prop up GP clinics.
Bushfire risk for those who move
Research suggests people who are forced to relocate after a bushfire are at a higher risk of PTSD.
COVIDSafe app scrapped
The COVIDSafe app has been scrapped, but little change is expected given that the app did not do much.
Fine for lack of RAT data
The Therapeutic Goods Administration (TGA) has fined two pharmaceutical companies over low quality rapid antigen tests (RATs).